ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$34.93
+1.51%Aug 28, 2026, 13:46 UTC
Roivant and Priovant Therapeutics launched their newly approved rare disease drug Lisraya at a list price of $35,000 for a 30-day supply on Friday.
Source:Aug 6, 2026, 11:00 UTC
Roivant is on track to launch brepocitinib for dermatomyositis by the end of September 2026.
Aug 6, 2026, 11:00 UTC
Roivant reported financial results for the first quarter ended June 30, 2026, with consolidated cash of $3.9 billion as of that date.
Source:Aug 6, 2026, 00:00 UTC
Roivant Sciences Ltd. repurchased 7.3 million shares of its common stock for approximately $208.7 million during Q1 2026.